SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
AssigneeKAHR Medical Ltd.
InventorsIris PECKER, Itai BLOCH
Life of this patent
Estimating the term…
Abstract
SIRPalpha-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a SIRPalpha variant. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein or the isolated polypeptide, host-cells expressing same and methods of use thereof.
Claims14
A method of treating colorectal cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a SIRPα-4-1BBL fusion protein as set forth in SEQ ID NO:
- 13, thereby treating the colorectal cancer.
A method of treating a disease comprising cells expressing CD47 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a SIRPα-4-1BBL fusion protein as set forth in SEQ ID NO:
- 13 and therapeutic agent for treating said disease other than said SIRPα-4-1BBL fusion protein, thereby treating the disease.
Dependencies are inferred from the claim text.